Lamivudine
- Generic Name
- Lamivudine
- Brand Names
- Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N3O3S
- CAS Number
- 134678-17-4
- Unique Ingredient Identifier
- 2T8Q726O95
- Background
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
- Indication
For the treatment of HIV infection and chronic hepatitis B (HBV).
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in Thailand
- Conditions
- Interventions
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2021-11-09
- Target Recruit Count
- 42
- Registration Number
- NCT00672412
- Locations
- 🇹🇭
Prapokklao Hosp. CRS, Muang District, Chantaburi, Thailand
🇹🇭Siriraj Hospital Mahidol University CRS, Bangkok, Ratchathewi, Thailand
🇹🇭Chonburi Hosp. CRS, Chonburi, Thailand
A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea
- Conditions
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 17
- Registration Number
- NCT00650637
- Locations
- 🇺🇸
Pfizer Investigational Site, Houston, Texas, United States
Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Pusan National University Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT00637663
- Locations
- 🇰🇷
Pusan National University School of Medicine, Busan, Korea, Republic of
🇰🇷Severance Hospital, Seoul, Korea, Republic of
Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2012-05-08
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 72
- Registration Number
- NCT00625560
- Locations
- 🇰🇷
Pusan National University School of Medicine, Busan, Korea, Republic of
🇰🇷Severance Hospital, Seoul, Korea, Republic of
Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2012-05-08
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 72
- Registration Number
- NCT00625339
- Locations
- 🇰🇷
Pusan National University School of Medicine, Busan, Korea, Republic of
🇰🇷Severance Hospital, Seoul, Korea, Republic of
Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- Avexa
- Target Recruit Count
- 239
- Registration Number
- NCT00612898
- Locations
- 🇺🇸
Summa Health System, Akron, Ohio, United States
🇺🇸Nicholaos C Bellos, MD, PA, Dallas, Texas, United States
🇺🇸University of Texas Medical Brach, Galveston, Texas, United States
Characterization of Acute and Recent HIV-1 Infections in Zurich.
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 800
- Registration Number
- NCT00537966
- Locations
- 🇨🇭
University of Zurich, Zurich, Switzerland
A Study to Investigate Whether the Immediate Use or Deferred Use of an Anti-viral Drug Lamivudine Will Help to Better Safe-guard the Delivery of Chemotherapy in Patients With Cancer Who Are Also Hepatitis B Carriers
- Conditions
- First Posted Date
- 2007-08-16
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- Hospital Authority, Hong Kong
- Target Recruit Count
- 110
- Registration Number
- NCT00516945
- Locations
- 🇨🇳
Queen Elizabeth Hospital, Hong Kong, China
A Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil for Prevention of zHBV Reactivation in HBsAg Seropositive Patients Undergoing Cytotoxic Chemotherapy
- Conditions
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2010-07-07
- Lead Sponsor
- Hospital Authority, Hong Kong
- Target Recruit Count
- 70
- Registration Number
- NCT00489151
- Locations
- 🇨🇳
Queen Mary Hospital, Hong Kong, China
Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus
- Conditions
- Interventions
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 629
- Registration Number
- NCT00410202
- Locations
- 🇺🇸
University Of Connecticut Health Center, Farmington, Connecticut, United States
🇹🇷Local Institution, Trabzon, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.